Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 01, 2026 | August 04, 2026 |
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| Neurogene Inc.AQXP · Entity 5160 | Director | March 23, 2017 | March 27, 2017 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 22,359 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Exercise / conversion · Acquired 403 · Balance 22,359 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 403 |
Reported balance
After 2026-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-01 · Grant · Acquired 403 · Balance 403 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-01 · Exercise / conversion · Disposed 403 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,469 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 22,469 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Neurogene Inc.
Report date March 23, 2017 · Filed March 27, 2017
This filing explicitly reported no securities owned.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.29 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010562 · form4-07032023_040708.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010562 · form4-07032023_040708.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 1,198 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016060 · doc4.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,298 F1 · kind: Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001213900-23-047467 · ownership.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009428 · form4-06082023_080610.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,236 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001415889-23-009428 · form4-06082023_080610.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,236 Underlying: Class A Common Shares · 26,236 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · derivative · entry 14 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F3 · derivative.exercise_date: All shares issued pursuant to the exercise of these options represent 10,000 shares underlying an option award of 10,000 shares. All exercised options vested June 27, 2020. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to buy) · Derivative | 12,489 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · derivative · entry 13 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of these options represent 12,489 shares underlying an option award of 12,489 shares. All exercised options vested June 17, 2022. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 500 | $296.68 | $148,340.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 12 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $296.43 to $296.77, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,325 | $295.45 | $686,921.25 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 11 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $295.26 to $296.15, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,164 | $294.68 | $1,521,727.52 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 10 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,925 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $294.17 to $295.16, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,548 | $293.54 | $1,041,479.92 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 9 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,089 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.12 to $294.11, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,227 | $292.68 | $1,529,838.36 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 8 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,637 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $292.11 to $293.09, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,325 | $291.66 | $969,769.50 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 7 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,864 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $291.08 to $292.07, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,600 | $290.36 | $464,576.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,189 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.80 to $290.79, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $288.91 | $86,673.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,789 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $288.73 to $289.01, inclusive. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $287.08 | $114,832.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,089 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.99 to $287.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $285.28 | $28,528.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,489 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 10,000 | $100.45 | $1,004,500.00 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 00:57 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 12,489 | $105.08 | $1,312,344.12 |
DisclosureSEC source: 0000899243-23-002219 · doc4.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:25 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-22-040842 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2023 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007105 · form4-06302022_010627.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-22-007105 · form4-06302022_010627.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 10:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0000899243-22-023231 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001213900-22-031994 · ownership.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 21:27 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (right to buy) · Derivative | 26,342 | Not disclosed Strike: $30.29 | Not disclosed |
DisclosureSEC source: 0001562180-21-004978 · primarydocument.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,342 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 21:27 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (right to buy) · Derivative | 13,171 | Not disclosed Strike: $33.57 | Not disclosed |
DisclosureSEC source: 0001562180-21-004978 · primarydocument.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,171 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:56 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 7,368 | $0.00 Strike: $93.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045040 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 Underlying: Common Stock · 7,368 shares Expires 2031-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2022 or one (1) day prior to Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001179110-21-007182 · edgar.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to buy) · Derivative | 12,489 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-21-024664 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 00:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039687 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:15 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 13,171 | $0.00 Strike: $33.57 | $0.00 |
DisclosureSEC source: 0000899243-21-022145 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,171 Underlying: Common Stock · 13,171 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2021, and the shares underlying the option vest in equal quarterly installments through June 2, 2022, subject to continued service. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,760 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001104659-20-080553 · a4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2030-06-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 01:11 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 7,106 | $0.00 Strike: $54.12 | $0.00 |
DisclosureSEC source: 0001209191-20-040825 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,106 Underlying: Common Stock · 7,106 shares Expires 2030-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 11:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0000899243-20-016985 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:43 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035852 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 00:17 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 4,135 | $0.00 Strike: $62.50 | $0.00 |
DisclosureSEC source: 0001209191-20-035717 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,135 Underlying: Common Stock · 4,135 shares Expires 2030-06-07 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 8, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 11:52 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 26,342 | $0.00 Strike: $30.29 | $0.00 |
DisclosureSEC source: 0000899243-20-010271 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,342 Underlying: Common Stock · 26,342 shares Expires 2030-04-02 F1 · derivative.exercise_date: This option was granted on April 3, 2020 and is scheduled to vest in equal monthly installments through April 3, 2023, subject to continued service. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:50 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | PurchaseCommon Stock | 750 | $44.65 | $33,487.50 |
DisclosureSEC source: 0001209191-20-020949 · doc4.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F2 · price: The price reported in Column 4 is a weighted-average price. The shares were purchased in multiple transactions ranging from $44.26 to $44.69, inclusive. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:50 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | PurchaseCommon Stock | 250 | $43.37 | $10,842.50 |
DisclosureSEC source: 0001209191-20-020949 · doc4.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · price: The price reported in Column 4 is a weighted-average price. The shares were purchased in multiple transactions ranging from $43.21 to $44.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set fort in these footnotes. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 00:13 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003235 · doc4.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 50% of the shares vest on January 10, 2021 and 1/24th of the shares vest monthly thereafter. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:59 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000899243-19-018677 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:20 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 24,747 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0000899243-19-015588 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,747 Underlying: Common Stock · 24,747 shares Expires 2029-06-02 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 3, 2020 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:27 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 37,965 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001104659-19-013172 · a4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,965 Underlying: Class A Common Shares · 37,965 shares Expires 2029-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to one third of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a twenty-four month period thereafter. The vesting commencement date is March 4, 2019. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 23:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $303.79 | $0.00 |
DisclosureSEC source: 0001179110-18-008928 · edgar.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 20:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 7 | $16.25 | $113.75 |
DisclosureSEC source: 0001179110-17-011806 · edgar.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 20:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 1,793 | $16.12 | $28,903.16 |
DisclosureSEC source: 0001179110-17-011806 · edgar.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,093 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 20:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 100 | $16.11 | $1,611.00 |
DisclosureSEC source: 0001179110-17-011806 · edgar.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 20:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 100 | $16.08 | $1,608.00 |
DisclosureSEC source: 0001179110-17-011806 · edgar.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 127 | $16.14 | $2,049.78 |
DisclosureSEC source: 0001179110-17-011766 · edgar.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.